<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hospach I</submitter><funding>Baxter</funding><pagination>14</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7221037</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8(1)</volume><pubmed_abstract>BACKGROUND:Invasive mechanical ventilation is lifesaving in the setting of severe acute respiratory failure but can cause ventilation-induced lung injury. Advances in extracorporeal CO2 removal (ECCO2R) technologies may facilitate more protective lung ventilation in acute respiratory distress syndrome, and enable earlier weaning and/or avoid invasive mechanical ventilation entirely in chronic obstructive pulmonary disease exacerbations. We evaluated the in vitro CO2 removal capacity of the novel PrismaLung+ ECCO2R device compared with two existing gas exchangers. METHODS:The in vitro CO2 removal capacity of the PrismaLung+ (surface area 0.8 m2, Baxter) was compared with the PrismaLung (surface area 0.35 m2, Baxter) and A.L.ONE (surface area 1.35 m2, Eurosets) devices, using a closed-loop b</pubmed_abstract><journal>Intensive care medicine experimental</journal><pubmed_title>In vitro characterization of PrismaLung+: a novel ECCO2R device.</pubmed_title><pmcid>PMC7221037</pmcid><funding_grant_id>N/A</funding_grant_id><pubmed_authors>Storr M</pubmed_authors><pubmed_authors>Harenski K</pubmed_authors><pubmed_authors>Laffey JG</pubmed_authors><pubmed_authors>Hospach I</pubmed_authors><pubmed_authors>Pouchoulin D</pubmed_authors><pubmed_authors>Goldstein J</pubmed_authors><pubmed_authors>Votteler S</pubmed_authors><pubmed_authors>Raible M</pubmed_authors></additional><is_claimable>false</is_claimable><name>In vitro characterization of PrismaLung+: a novel ECCO2R device.</name><description>BACKGROUND:Invasive mechanical ventilation is lifesaving in the setting of severe acute respiratory failure but can cause ventilation-induced lung injury. Advances in extracorporeal CO2 removal (ECCO2R) technologies may facilitate more protective lung ventilation in acute respiratory distress syndrome, and enable earlier weaning and/or avoid invasive mechanical ventilation entirely in chronic obstructive pulmonary disease exacerbations. We evaluated the in vitro CO2 removal capacity of the novel PrismaLung+ ECCO2R device compared with two existing gas exchangers. METHODS:The in vitro CO2 removal capacity of the PrismaLung+ (surface area 0.8 m2, Baxter) was compared with the PrismaLung (surface area 0.35 m2, Baxter) and A.L.ONE (surface area 1.35 m2, Eurosets) devices, using a closed-loop b</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 May</publication><modification>2025-06-01T03:23:01.083Z</modification><creation>2020-05-22T20:13:29Z</creation></dates><accession>S-EPMC7221037</accession><cross_references><pubmed>32405714</pubmed><doi>10.1186/s40635-020-00301-7</doi></cross_references></HashMap>